product summary
Loading...
company name :
BioLegend
other brands :
Babco, Signet, Sternberger Monoclonals, Senetek, Covance
product type :
antibody
product name :
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready)
catalog :
329719
quantity :
100 μg
price :
136 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
29E.2A3
reactivity :
human, mouse
application :
flow cytometry, immunohistochemistry - paraffin section, blocking or activating experiments, mass cytometry
more info or order :
citations: 52
Published Application/Species/Sample/DilutionReference
  • flow cytometry; human; loading ...; fig s1c
Morrissey M, Byrne R, Nulty C, McCabe N, Lynam Lennon N, Butler C, et al. The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. BMC Cancer. 2020;20:566 pubmed publisher
  • mass cytometry; human; loading ...; fig 4d
Fu W, Wang W, Li H, Jiao Y, Weng J, Huo R, et al. High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas. Front Oncol. 2020;10:78 pubmed publisher
  • flow cytometry; human; loading ...; fig s1a
Jordan S, Tung N, Casanova Acebes M, Chang C, Cantoni C, Zhang D, et al. Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. Cell. 2019;178:1102-1114.e17 pubmed publisher
  • flow cytometry; human; loading ...; fig 4e
Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  • flow cytometry; human; loading ...; fig 5b, 5d, e4f
Mendoza J, Escalante N, Jude K, Sotolongo Bellon J, Su L, Horton T, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56-60 pubmed publisher
  • flow cytometry; human; 1:300; loading ...; fig s1b
Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher
  • flow cytometry; human; loading ...; fig 1c
Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher
  • flow cytometry; human; loading ...; fig s5a
Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher
  • flow cytometry; mouse; 1:200; loading ...; fig s1a
Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher
  • blocking or activating experiments; human; loading ...; fig 6c
Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher
  • flow cytometry; human; loading ...; fig 1d
Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher
  • flow cytometry; human; fig s4b
Martin Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, et al. Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight. 2017;2:e89574 pubmed publisher
  • flow cytometry; human; 1:100; fig 5a
Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher
  • flow cytometry; human; fig 4
Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
  • flow cytometry; human; loading ...; fig s1
Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  • flow cytometry; human; fig s6b
Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  • flow cytometry; human; 1:200; fig 2
Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  • blocking or activating experiments; human
  • flow cytometry; human; fig 7
Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
  • flow cytometry; human; fig 6
Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  • flow cytometry; human; loading ...; fig 1
Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  • flow cytometry; human; fig 2
Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed
  • immunohistochemistry - paraffin section; human; 1:50
Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  • flow cytometry; human; fig 4
Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher
Ganan Gomez I, Yang H, Ma F, Montalban Bravo G, Thongon N, Marchica V, et al. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022;28:557-567 pubmed publisher
Hezaveh K, Shinde R, Kl xf6 tgen A, Halaby M, Lamorte S, Ciudad M, et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity. 2022;55:324-340.e8 pubmed publisher
Mishra A, Lai G, Yao L, Aung T, Shental N, Rotter Maskowitz A, et al. Microbial exposure during early human development primes fetal immune cells. Cell. 2021;184:3394-3409.e20 pubmed publisher
Roussel M, Ferrant J, Reizine F, Le Gallou S, Dulong J, Carl S, et al. Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. Cell Rep Med. 2021;2:100291 pubmed publisher
Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
Merola J, Reschke M, Pierce R, Qin L, Spindler S, Baltazar T, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight. 2019;4: pubmed publisher
Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt M, Hermanns H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38:397 pubmed publisher
Kim D, Kim H, Choi Y, Kim S, Lee J, Sung K, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51:94 pubmed publisher
Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher
Sueyoshi K, Ledderose C, Shen Y, Lee A, Shapiro N, Junger W. Lipopolysaccharide suppresses T cells by generating extracellular ATP that impairs their mitochondrial function via P2Y11 receptors. J Biol Chem. 2019;294:6283-6293 pubmed publisher
Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;: pubmed publisher
Ahmed A, Adiga V, Nayak S, Uday Kumar J, Dhar C, Sahoo P, et al. Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis. PLoS Pathog. 2018;14:e1007289 pubmed publisher
Wang B, Zuo J, Kang W, Wei Q, Li J, Wang C, et al. Generation of Hutat2:Fc Knockin Primary Human Monocytes Using CRISPR/Cas9. Mol Ther Nucleic Acids. 2018;11:130-141 pubmed publisher
Chaganty B, Qiu S, Gest A, Lu Y, Ivan C, Calin G, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion. Cancer Lett. 2018;430:47-56 pubmed publisher
Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L, et al. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;: pubmed publisher
Wilson J, Zhao Y, Singer M, Spencer J, Shankar Hari M. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. Crit Care. 2018;22:95 pubmed publisher
Yamada S, Itai S, Kaneko M, Kato Y. Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. Biochem Biophys Rep. 2018;13:123-128 pubmed publisher
Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher
Alcántara Hernández M, Leylek R, Wagar L, Engleman E, Keler T, Marinkovich M, et al. High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity. 2017;47:1037-1050.e6 pubmed publisher
Salio M, Gasser O, González López C, Martens A, Veerapen N, Gileadi U, et al. Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. J Immunol. 2017;199:2631-2638 pubmed publisher
Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker J, et al. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol. 2017;199:604-612 pubmed publisher
Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher
Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher
Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
Daley D, Zambirinis C, Seifert L, Akkad N, Mohan N, Werba G, et al. ?? T Cells Support Pancreatic Oncogenesis by Restraining ?? T Cell Activation. Cell. 2016;166:1485-1499.e15 pubmed publisher
Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher
Chang Z, Silver P, Chen Y. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. J Transl Med. 2015;13:161 pubmed publisher
Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher
product information
Antigen :
CD274
Apps. Abbrev. :
FC, CyTOF®
Cat # :
329719
Clone :
29E.2A3
Item :
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready)
Isotype :
Mouse IgG2b, κ
Other Names :
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Size :
100 μg
Price (USD) :
136 USD
Reactivity :
Human
Clonality :
Monoclonal
Host :
Mouse
Conjugate/Tag/Label :
PUREMAX
Immunogen :
Full length human PD-L1
Application Notes :
Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region^5. Additional reported applications (for the relevant formats) include: blocking^1-3 and immunohistochemical staining of acetone-fixed frozen sections^1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.;Clone 29E.2A3 does not work in Western blot applications^7.;
more info or order :
company information
BioLegend
8999 BioLegend Way
San Diego, CA 92121
customerserv@biolegend.com
https://www.biolegend.com
headquarters: USA